Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer (mCRPC)

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|116|1|17-29

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.116, Iss.1, 2015-07, pp. : 17-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Immunotherapy in Castration‐Resistant Prostate Cancer (CRPC)

By  

BJU INTERNATIONAL, Vol. 113, Iss. 3, 2014-03 ,pp. : 367-375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy

By  

Case Reports in Oncology, Vol. 6, Iss. 2, 2013-06 ,pp. : 325-330

Karger

Access to resources Recommend Favorite

Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer

By  

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 833-839

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabazitaxel for the therapy of metastatic castration‐resistant prostate cancer in the aftermath of the CHAARTED trial

By  

BJU INTERNATIONAL, Vol. 116, Iss. 6, 2015-12 ,pp. : 839-840

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is angiogenesis still an attractive target in metastatic castration‐resistant prostate cancer?

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 500-501

John Wiley & Sons Inc

Access to resources Recommend Favorite